Curexo (060280) Fundamentals 2026 — P/E 155.0x, Revenue Analysis | SniperIQ
Curexo (060280) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩330.1B, trading at ₩8000.00 on the KOE. This SniperIQ fundamentals page covers Curexo's valuation (P/E 155.0x, P/B 3.3x), profitability (net margin 3.0%), revenue (₩74.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Curexo's market cap?
Curexo (060280) has a market capitalization of approximately ₩330.1B, trading at ₩8000.00 on the KOE. Market cap moves with the live share price.
What is Curexo's P/E ratio?
Curexo's trailing twelve-month P/E ratio is 155.0x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Curexo?
Curexo runs a net profit margin of 3.0%, a gross margin of 31.8%, and an operating margin of 0.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Curexo generate?
Curexo reported revenue of ₩74.5B for fiscal year 2025, with net income of ₩2.8B and earnings per share (EPS) of 67.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Curexo pay a dividend?
Curexo does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Curexo financially healthy?
Curexo carries a debt-to-equity ratio of 0.01x and a current ratio of 16.73x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Curexo a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Curexo (060280) the key facts are: market cap ₩330.1B, P/E 155.0x, revenue ₩74.5B, 52-week range 7460-22550. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Curexo's full fundamentals live
Get Curexo's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.